北京大学学报(医学版) ›› 2024, Vol. 56 ›› Issue (3): 533-540. doi: 10.19723/j.issn.1671-167X.2024.03.022

• 论著 • 上一篇    下一篇

成人及儿童组织坏死性淋巴结炎临床特征及治疗

费秀文1,刘斯1,汪波1,*(),董爱梅2   

  1. 1. 北京大学第一医院急诊科,北京 100034
    2. 北京大学第一医院全科医学科,北京 100034
  • 收稿日期:2024-01-18 出版日期:2024-06-18 发布日期:2024-06-12
  • 通讯作者: 汪波 E-mail:bjwbdoctor@163.com

Clinical characteristics and treatment in adults and children with histiocytic necroti-zing lymphadenitis

Xiuwen FEI1,Si LIU1,Bo WANG1,*(),Aimei DONG2   

  1. 1. Department of Emergency, Peking University First Hospital, Beijing 100034, China
    2. Department of General Practice, Peking University First Hospital, Beijing 100034, China
  • Received:2024-01-18 Online:2024-06-18 Published:2024-06-12
  • Contact: Bo WANG E-mail:bjwbdoctor@163.com

RICH HTML

  

摘要:

目的: 分析组织坏死性淋巴结炎(histiocytic necrotizing lymphadenitis, HNL)的临床资料, 比较成人及儿童临床资料的异同, 加深临床医师对该病的认识, 提高诊断率, 减少误诊、误治。方法: 收集北京大学第一医院2010年1月至2023年8月活检病理诊断为组织坏死性淋巴结炎住院患者的临床资料, 分析组织坏死性淋巴结炎的临床特征、实验室检查、病理特征、抗生素及糖皮质激素治疗及转归情况。根据年龄进行分组, 比较儿童组(<16岁)和成人组(≥16岁)患者上述临床资料的差异。结果: 入组的81例患者中, 男42例, 女39例, 中位年龄为21(14, 29)岁, 中位病程为20.0(13.0, 30.0) d, 中位住院时长为13.0(10.0, 15.0) d。首发症状有发热、淋巴结肿大及发热和淋巴结肿大同时起病。所有患者均有不同部位、不同大小的淋巴结肿大, 96.3%(78/81)的患者伴颈部淋巴结肿大, 双侧颈部淋巴结都肿大者占50.6%(41/81), 锁骨上、腋窝或腹股沟淋巴结肿大者占55.6%(45/81), 中位淋巴结直径为20.0(20.0, 30.0) mm。仅有1例患者不伴有发热, 其余80例患者均有发热, 中位峰值体温为39.0(38.0, 39.8) ℃。伴随症状: 皮疹7例(8.6%, 7/81)、乏力28例(34.6%, 28/81)、盗汗7例(8.6%, 7/81)、畏寒寒战25例(25.3%, 25/81)、肌肉酸痛11例(13.6%, 11/81)、关节痛5例(6.2%, 5/81)。肝脾肿大有17例(21.0%, 17/81), 其中脾大12例, 占肝脾大的70.6%(12/17)。68.8%(55/80)的患者白细胞(white blood cells, WBC)计数下降, 47.5%(38/80)淋巴细胞(lymphocyte, LY)比例升高, 53.4%(39/73)超敏C反应蛋白(C-reactive protein, CRP)升高, 79.2%(57/72)红细胞沉降率(erythrocyte sedimentation rate, ESR)升高, 22.2%(18/81)谷丙转氨酶(alanine transaminase, ALT)升高, 27.2%(22/81)谷草转氨酶(aspartate transaminase, AST)升高, 81.6%(62/76)乳酸脱氢酶(lactate dehydrogenase, LDH)升高。81例患者均进行了淋巴结活检病理检查, 77.8%(63/81)的患者淋巴结活检病理组织学表现为淋巴结内结构大部分破坏或消失, 16.0%(13/81)淋巴结结构尚存或存在, 淋巴结结构增生、淋巴结结构正常各占1.2%(1/81), 3.7%(3/81)的患者未记录淋巴结结构。67例进行了免疫组织化学染色, CD3+、CD68(KP1)+分别占97.0%(65/67), MPO+占94.0%(63/67)。51例(63.0%, 51/81)患者在明确诊断后给予糖皮质激素治疗, 其中糖皮质激素治疗后体温恢复正常的中位数时间为1.0(1.0, 4.0) d, 糖皮质激素治疗效果最好时体温可当天下降至正常。成人组和儿童组在住院时长、是否有前驱诱因、是否伴随畏寒寒战、超敏CRP升高率、是否应用抗生素、是否应用糖皮质激素治疗方面差异有统计学意义(P<0.05)。结论: 临床上如出现不明原因发热、浅表淋巴结肿大及白细胞减少为临床特征的病例, 且一般抗感染药物治疗无效时, 应考虑组织坏死性淋巴结炎, 需尽早行淋巴结活检以明确诊断, 减少误诊、误治, 治疗以对症治疗为主, 糖皮质激素治疗疗效确切。

关键词: 组织坏死性淋巴结炎, 成人, 儿童

Abstract:

Objective: To analyze the clinical data of histiocytic necrotizing lymphadenitis(HNL), comparing the similarities and differences between children and adults, to deepen the understanding of the disease by clinical physicians, and to improve diagnostic rate and reduce misdiagnosis and mistreatment. Methods: The clinical data of hospitalized patients with histiocytic necrotizing lymphadenitis diagnosed by biopsy from January 2010 to August 2023 in Peking University First Hospital were collec-ted, and the clinical features, laboratory examinations, pathological features, treatments with antibiotics and glucocorticoids, and prognosis of histiocytic necrotic lymphadenitis were analyzed. Grouped based on age, the differences of clinical characteristics, laboratory tests, treatment, and prognosis between the children group (< 16 years old) and the adult group (≥16 years old) were compared. Results: Among the 81 enrolled patients, there were 42 males and 39 females. The median age was 21(14, 29) years, the median duration of disease was 20.0(13.0, 30.0) days, and the median length of hospital stay was 13.0 (10.0, 15.0) days. The first symptoms were fever, lymphadenopathy, and both. All the patients had enlarged lymph nodes with different parts and sizes, 96.3% (78 of 81) of the patients had cervical lymphadenopathy, 50.6% (41 of 81) had bilateral cervical lymphadenopathy, 55.6% (45 of 81) had supraclavicular, axillary or inguinal lymphadenopathy, and the median lymph node diameter was 20.0(20.0, 30.0) mm. Only one patient had no fever, the other 80 patients had fever, the median peak body temperature was 39.0(38.0, 39.8) ℃. Accompanying symptoms: rash (8.6%, 7/81), fatigue (34.6%, 28/81), night sweating (8.6%, 7/81), chills (25.3%, 25/81), muscle soreness (13.6%, 11/81), and joint pain (6.2%, 5/81). There were 17 cases (21.0%, 17/81) of hepatosplenomegaly, of which 12 cases (70.6%, 12/17) were splenomegaly. 68.8%(55/80) of patients had a decrease in white blood cell (WBC) count, with 47.5%(38/80)increased in lymphocyte(LY)proportion, 53.4%(39/73) increased in high-sensitivity C-reactive protein(CRP), 79.2%(57/72) increased in erythrocyte sedimentation rate(ESR), 22.2%(18/81) increased in alanine transaminase(ALT), 27.2%(22/81) elevated in aspartate transaminase(AST), and 81.6%(62/76) elevated in lactate dehydrogenase(LDH). All the 81 patients underwent lymph node biopsy, and 77.8%(63/81) of the patients showed that most of the structures in the lymph nodes were destroyed or disappeared, and 16.0%(13/81) of the lymph nodes were still in existence, hyperplasia and normal lymph node were 1.2%(1/81) respectively, and 3.7%(3/81) had normal lymph node structures. Immunohistochemical staining was performed in 67 cases. The percentages of CD3+ and CD68(KP1)+ were respectively 97.0%(65/67), and MPO+ were 94.0%(63/67). In the study, 51 patients (63.0%, 51/81) were treated with glucocorticoid therapy after diagnosis. The median time for temperature to return to normal was 1.0(1.0, 4.0) days after glucocorticoid therapy. when the glucocorticoid treatment worked best, the body temperature could drop to normal on the same day. There were significant differences in length of stay, predisposing factors, chills, the rate of increase in high-sensitivity CRP, antibiotic and glucocorticoid treatment between the adults and children groups (P < 0.05). Conclusion: In clinical practice, if there are cases with unexplained fever, superficial lymph node enlargement, and reduced white blood cells as clinical characteristics, and general antibiotics treatment is ineffective, histiocytic necrotic lymphadenitis should be considered. Lymph node biopsy should be performed as early as possible to clarify the diagnosis, reduce misdiagnosis and mistreatment, and symptomatic treatment should be the main treatment. Glucocorticoids therapy has a definite therapeutic effect.

Key words: Histiocytic necrotic lymphadenitis, Adult, Children

中图分类号: 

  • R551.2

表1

儿童组和成人组临床情况比较"

Items Children Adults Mann-Whitney U P
Length of stay/d 11.0 (9.0, 13.5) 14.0 (10.0, 17.6) 579.50 0.026
Peak temperature/℃ 39.0 (38.3, 39.0) 39.0 (38.0, 40.0) 678.00 0.242
Diameter of lymph node/mm 21.0 (18.0, 25.0) 20.0 (20.0, 30.0) 643.50 0.333
Normal time of temperature with post-glucocorticoid/d 1.0 (1.0, 3.0) 1.5 (1.0, 5.0) 154.50 0.277

表2

儿童组和成人组临床表现比较"

Items Children Adults χ2/Fisher P
Precursor triggers 9.617 0.002
  No 34 (91.9) 26 (59.1)
  Yes 3 (8.1) 18 (40.9)
First symptoms 1.011 0.603
  Fever 15 (40.5) 20 (45.5)
  Swollen lymph nodes 13 (35.1) 11 (25.0)
  Double 9 (24.3) 13 (29.5)
Rash 0.445a
  No 35 (94.6) 39 (88.6)
  Yes 2 (5.4) 5 (11.4)
Fatigue 3.160 0.075
  No 28 (75.7) 25 (56.8)
  Yes 9 (24.3) 19 (43.2)
Night sweats 0.119a
  No 36 (97.3) 38 (86.4)
  Yes 1 (2.7) 6 (13.6)
Chills 4.555 0.033
  No 30 (81.1) 26 (59.1)
  Yes 7 (18.9) 18 (40.9)
Muscle soreness 0.445 0.505
  No 33 (89.2) 37 (84.1)
  Yes 4 (10.8) 7 (15.9)
Joint pain 0.369a
  No 36 (97.3) 40 (90.9)
  Yes 1 (2.7) 4 (9.1)
Hepatosplenomegaly 0.457 0.499
  No 28 (75.7) 36 (81.8)
  Yes 9 (24.3) 8 (18.2)

表3

儿童组和成人组实验室检查结果比较"

Items Children Adults χ2/Fisher P
WBC/(×109/L) 0.045 0.832
  <3.5 25 (67.6) 30 (69.8)
  ≥3.5 12 (32.4) 13 (30.2)
CRP/(mg/L) 20.419 0.000
  <8.0 24 (75.0) 9 (22.0)
  ≥8.0 8 (25.0) 32 (78.0)
ESR/(mm/h) 0.122 0.727
  <15 7 (21.2) 7 (17.9)
  ≥15 26 (78.8) 32 (82.1)
ALT/(IU/L) 2.221 0.136
  <50 26 (70.3) 37 (84.1)
  ≥50 11 (29.7) 7 (15.9)
AST/(IU/L) 0.582 0.445
  <40 24 (64.9) 32 (72.7)
  ≥40 13 (35.1) 12 (27.3)
LDH/(IU/L) 0.288 0.592
  <240 5 (15.6) 9 (20.5)
  ≥240 27 (84.4) 35 (79.5)
ANA 0.351 0.553
  Positive 12 (34.3) 10 (27.8)
  Negative 23 (65.7) 26 (72.2)
ENA 1.000a
  Positive 3 (34.3) 3 (9.1)
  Negative 30 (85.7) 30 (90.9)
EBV antibody 0.555 0.456
  Positive 26 (83.9) 26 (76.5)
  Negative 5 (16.1) 8 (23.5)
CMV antibody 0.006 0.936
  Positive 23 (71.9) 22 (71.0)
  Negative 9 (28.1) 9 (29.0)
Human parvovirus B19 antibody 0.167a
  Positive 0 (0) 1 (50.0)
  Negative 10 (100) 1 (50.0)

表4

儿童组和成人组治疗情况比较"

Items Children Adults χ2 P
Antibiotics 15.548 0.000
  No 4 (10.8) 23 (52.3)
  Yes 33 (89.2) 21 (47.7)
Glucocorticoid 8.458 0.004
  No 20 (54.1) 10 (22.7)
  Yes 17 (45.9) 34 (77.3)
1 Bosch X , Guilabea A , Miquel R , et al. Enigmatic Kikucli-Fujimoto disease: A comprehensive review[J]. Am J Clin Pathol, 2004, 122 (1): 141- 152.
doi: 10.1309/YF081L4TKYWVYVPQ
2 Ohshima K , Kikuchi M , Sumiyoshi Y , et al. Proliferating cells in histiocytic necrotizing lymphadenitis[J]. Virchows Arch B Cell Pathol Incl Mol Pathol, 1991, 61 (2): 97- 100.
3 杨进孙, 王文节, 杨江华. 组织细胞坏死性淋巴结炎25例临床及病理特征分析[J]. 皖南医学院学报, 2018, 37 (1): 19- 21.
4 Lebe E . Kikuchi-Fujimoto disease[J]. Kulak Burun Bogaz Ihtis Derg, 2014, 24 (3): 164- 167.
doi: 10.5606/kbbihtisas.2014.62447
5 王艳, 巩小丽, 黄有清, 等. 组织细胞坏死性淋巴结炎误诊误治讨论[J]. 临床误诊误治, 2015, 28 (2): 31- 33.
6 Pepe F , Disma S , Teodoro C , et al. Kikuchi-Fujimoto disease: A clinicopathologic update[J]. Pathologica, 2016, 108 (3): 120- 129.
7 Xu Z , Liu Y , Li H , et al. Detection of mycobacterial and viral DNA in Kikuchi-Fujimoto disease: An analysis of 153 Chinese pediatric cases[J]. Sci China Life Sci, 2017, 60 (7): 775- 777.
doi: 10.1007/s11427-017-9087-6
8 Hall LD , Eminger LA , Hesterman KS , et al. Epstein-Barr virus: Dermatologic associations and implications: Part Ⅰ. Mucocutaneous manifestations of Epstein-Barr virus and nonmalignant disorders[J]. J Am Acad Dermatol, 2015, 72 (1): 1- 19.
doi: 10.1016/j.jaad.2014.07.034
9 Deaver D , Horna P , Cualing H , et al. Pathogenesis, diagnosis, and management of Kikuchi-Fujimoto disease[J]. Cancer Control, 2014, 21 (4): 313- 321.
doi: 10.1177/107327481402100407
10 Chong Y , Kang CS . Causative agents of Kikuchi-Fujimoto disease (histiocytic necrotizing lymphadenitis): A meta analysis[J]. Int J Pediatr Otorhinolaryngol, 2014, 78 (11): 1890- 1897.
doi: 10.1016/j.ijporl.2014.08.019
11 Feder HM Jr , Liu J , Rezuke WN . Kikuchi disease in connecticut[J]. J Pediatr, 2014, 164 (1): 196- 200.
doi: 10.1016/j.jpeds.2013.08.041
12 Fiorella ML , Gelardi M , Marzullo A , et al. Kikuchi-Fujimoto disease: An uncommon cause of neck swelling[J]. Eur Arch Otorhinolaryngol, 2017, 274 (3): 1761- 1764.
doi: 10.1007/s00405-016-4147-6
13 Dalugama C , Gawarammana IB . Fever with lym-phadenopathy: Kikuchi-Fujimoto disease, a great masquerader[J]. J Med Case Rep, 2017, 11 (1): 349.
doi: 10.1186/s13256-017-1521-y
14 Jung IY , Ann HW , Kim JJ , et al. The incidence and clinical characteristics by gender differences in patients with Kikuchi-Fujimoto disease[J]. Medicine (Baltimore), 2017, 96 (11): e6332.
doi: 10.1097/MD.0000000000006332
15 Perry AM , Choi SM . Kikuchi-Fujimoto disease: A review[J]. Arch Pathol Lab Med, 2018, 142 (11): 1341- 1346.
doi: 10.5858/arpa.2018-0219-RA
16 王宁, 王尧, 王晓, 等. 51例菊池病患者临床资料回顾性分析[J]. 内科理论与实践, 2019, 14 (4): 214- 218.
17 Yen HR , Lin PY , Chuang WY , et al. Skin manifestations of Kikuchi-Fujimoto disease: Case report and review[J]. Eur J Pediatr, 2004, 163 (4/5): 210- 213.
18 费秀文, 迟春花, 狄娜, 等. 组织增生坏死性淋巴结炎一例[J]. 中华全科医师杂志, 2020, 19 (3): 253- 255.
19 刘改萍, 田芳. 组织细胞坏死性淋巴结炎9例临床病理及彩超变化的探讨[J]. 山西医科大学学报, 2006, 37 (4): 402- 404.
20 郑杨. 组织细胞坏死性淋巴结炎的诊断、鉴别诊断及其治疗[J]. 中国医刊, 2010, 45 (12): 12- 15.
21 Dumas G , Prendki V , Haroche J , et al. Kikuchi-Fujimoto disease: Retrospective study of 91 case sand review of the literature[J]. Medicine (Baltimore), 2014, 93 (24): 372- 382.
22 宋红杰, 马捷. 组织细胞坏死性淋巴结炎的研究进展[J]. 临床与实验病理学杂志, 2015, 31 (5): 569- 571.
23 Bezek S , Tucci V , Kalra S , et al. State of the globe: Time tore visit Kikuchi-Fujimoto disease[J]. J Glob Infect Dis, 2014, 6 (4): 139- 140.
[1] 李宗瀚, 黄洋阅, 李宁, 李明磊, 宋宏程, 张潍平, 刘超. 国产单孔蛇形臂机器人手术系统在儿童肾盂成形术中的应用[J]. 北京大学学报(医学版), 2025, 57(4): 662-665.
[2] 赵兆, 张维宇, 杨文博, 张勇杰, 张晓鹏, 赵慧颖, 周刚, 王强. 低龄、低体重儿童肾移植2例[J]. 北京大学学报(医学版), 2025, 57(4): 803-807.
[3] 张依航, 蔡珊, 陈子玥, 刘云飞, 党佳佳, 师嫡, 李佳欣, 黄天彧, 宋逸. 基于RE-AIM框架儿童青少年近视与肥胖共病综合干预实施性研究结局指标的构建[J]. 北京大学学报(医学版), 2025, 57(3): 436-441.
[4] 唐孟利, 刘扬, 秦冉, 郭欣, 李宏田. 我国10省幼儿园5~6岁儿童近视和近视前期流行特征[J]. 北京大学学报(医学版), 2025, 57(3): 442-447.
[5] 刘光旭, 张良, 赵厚宇, 邓思危, 杨君婷, 李宁, 马瑞, 何艳, 许国章, 刘志科, 詹思延. 2015—2021年宁波市6岁以下儿童热性惊厥的流行病学特征[J]. 北京大学学报(医学版), 2025, 57(3): 584-591.
[6] 李琳, 廖津津. 应用ROC曲线评估久坐行为对儿童青少年视力不良的预测价值[J]. 北京大学学报(医学版), 2025, 57(3): 614-619.
[7] 王紫薇, 李闵, 高慧, 邓芳. 链球菌感染与过敏性紫癜肾炎患儿肾损害的相关性[J]. 北京大学学报(医学版), 2025, 57(2): 284-290.
[8] 邓敏婷, 王楠, 夏斌, 赵玉鸣, 朱俊霞. 儿童及青少年挫入恒前牙自行再萌出的相关影响因素[J]. 北京大学学报(医学版), 2025, 57(1): 148-153.
[9] 杨颖婷, 李若竹, 窦桂丽, 雷玥, 夏斌. iRoot BP Plus用于年轻恒牙外伤部分牙髓切断治疗的临床随机对照研究[J]. 北京大学学报(医学版), 2024, 56(6): 1083-1088.
[10] 赵双云, 邹思雨, 李雪莹, 沈丽娟, 周虹. 中文版口腔健康素养量表简版(HeLD-14)在学龄前儿童家长中应用的信度和效度评价[J]. 北京大学学报(医学版), 2024, 56(5): 828-832.
[11] 陈心心, 唐哲, 乔艳春, 荣文笙. 北京市密云区4岁儿童患龋状况及其与龋活跃性检测的相关性[J]. 北京大学学报(医学版), 2024, 56(5): 833-838.
[12] 岳芷涵,韩娜,鲍筝,吕瑾莨,周天一,计岳龙,王辉,刘珏,王海俊. 儿童早期体重指数轨迹与超重风险关联的前瞻性队列研究[J]. 北京大学学报(医学版), 2024, 56(3): 390-396.
[13] 俞光岩. 儿童唾液腺疾病[J]. 北京大学学报(医学版), 2024, 56(1): 1-3.
[14] 姚海红,杨帆,唐素玫,张霞,何菁,贾园. 系统性红斑狼疮及成人Still病合并巨噬细胞活化综合征的临床特点及诊断指标[J]. 北京大学学报(医学版), 2023, 55(6): 966-974.
[15] 闫晓晋,刘云飞,马宁,党佳佳,张京舒,钟盼亮,胡佩瑾,宋逸,马军. 《中国儿童发展纲要(2011-2020年)》实施期间中小学生营养不良率变化及其政策效应分析[J]. 北京大学学报(医学版), 2023, 55(4): 593-599.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!